The reliable epidemiological information regarding eumycetoma is limited even though it was first reported from India in the middle of the 19th century.
Aspergillus species are uncommon cause of eumycetoma. Many antifungals showed higher MIC values against this isolate.
 Differentiation between actinomycetoma and eumycetoma is important because of their differences in response to treatment.
Fosravuconazole, an azole-class antifungal drug discovered by Eisai, has shown in vitro and in vivo to have strong antifungal activities against eumycetoma. Under the terms of the agreement, DNDi and partners will be conducting the clinical development to assess safety and efficacy of fosravuconazole in patients with the disease, while Eisai provides DNDi with its scientific expertise as well as a supply of the drug for the clinical studies.
"Eumycetoma patients have received little attention and virtually no research and development has addressed their needs."
Fosravuconazole will be investigated in a randomized controlled trial to study the efficacy of the drug compared to an existing therapy in moderate eumycetoma cases.
A painful thorn in the foot: A case of eumycetoma
. Am J Med Sci 2007;334(2):142-144.
3 The most common cause of eumycetoma
(commonly, mycetoma foot) in the United States is:
Here, we report a rare case of Eumycetoma due to Curvularia lunata with a unique presentation.
Thus, a diagnosis of Eumycetoma due to Curvularia lunata was reached.
Mycetoma caused by microaerophilic actinomycetes is termed actinomycetoma, and mycetoma caused by true fungi is called eumycetoma. The disease was described in 1842 and initially named Madura foot, after the region of Madurai in India where it was first identified (3).
Combined medical (antifungal agents) and surgical treatment is standared for eumycetoma. Actinomycetoma is a bacterial infection, respond to antibiotics.